

References

1. Platinol. Physicians Desk Reference. Medical Economics Company, Montvale, New Jersey, 1998; 717-721.
2. Ihde DC. Chemotherapy of lung cancer. *N Engl J Med* 1992; 327(20):1434-1441.
3. Lilenbaum RC, Green MR. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. *J Clin Oncol* 1993; 11(7):1391-1402.
4. McKeage MJ. Comparative adverse effect profiles of platinum drugs. *Drug Saf* 1995; 13(4):228-244.
5. Desoize B, Marechal F, Millart H, Cattan A. Correlation of clinical pharmacokinetic parameters of cisplatin with efficacy and toxicity. *Biomed Pharmacother* 1991; 45(4-5):203-207.
6. Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GP Jr. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. *Cancer Res* 1988; 48(13):3869-3874.
7. Nagai N, Kinoshita M, Ogata H, Tsujino D, Wada Y, Someya K, et al. Relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer patients. *Cancer Chemother Pharmacol* 1996; 39(1-2):131-137.

8. Brillet G, Deray G, Rottembourg J. Definitive renal failure after one course of cisplatin [letter]. *Nephrol Dial Transplant* 1993; 8(6):573-574.
9. Brillet G, Deray G, Jacquiaud C, Mignot L, Bunker D, Meillet D, et al. Long-term renal effect of cisplatin in man. *Am J Nephrol* 1994; 14(2):81-84.
10. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. A review. *Cancer Chemother Pharmacol* 1989; 25(1):1-9.
11. Fjeldborg P, Sorensen J, Helkjaer PE. The long-term effect of cisplatin on renal function. *Cancer* 1986; 58(10):2214-2217.
12. Goren MP, Wright RK, Horowitz ME. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. *Cancer Chemother Pharmacol* 1986; 18(1):69-73.
13. Hamilton CR, Bliss JM, Horwich A. The late effects of cisplatin on renal function. *Eur J Cancer Clin Oncol* 1989; 25(2):185-189.
14. Jaffe N, Keifer R III, Robertson R, Cangir A, Wang A. Renal toxicity with cumulative doses of cis-diamminedichloro platinum-II in pediatric patients with osteosarcoma. Effect on creatinine clearance and methotrexate excretion. *Cancer* 1987; 59(9):1577-1581.
15. De Santo NG, Capasso G, Capodicasa G, Tancredi F, Nuzzi F, Giordano C. Acute renal failure due to cisplatin. *Int J Pediatr Nephrol* 1986; 7(3):145-150.

16. Gomez Campdera FJ, Gonzalez P, Carrillo A, Estelles MC, Rengel M. Cisplatin nephrotoxicity: symptomatic hypomagnesemia and renal failure. *Int J Pediatr Nephrol* 1986; 7(3):151-152.
17. Markmann M, Rothman R, Reichman B, Hakes T, Lewis JL, Jr., Rubin S, et al. Persistent hypomagnesemia following cisplatin chemotherapy in patients with ovarian cancer. *J Cancer Res Clin Oncol* 1991; 117(2):89-90.
18. Wadd NJ, Tiplady C, Roberts JT. Cisplatin and acute tubular necrosis. *Clin Oncol (R Coll Radiol)* 1997; 9(4):267-268.
19. Bellin SL, Selim M. Cisplatin-induced hypomagnesemia with seizures: a case report and review of the literature. *Gynecol Oncol* 1988; 30(1):104-113.
20. Cohen L. Potassium replacement associated with the development of tetany in a patient with hypomagnesaemia. *Magnes Res* 1993; 6(1):43-45.
21. Mavichak V, Coppin CM, Wong NL, Dirks JH, Walker V, Sutton RA. Renal magnesium wasting and hypocalciuria in chronic cis-platinum nephropathy in man. *Clin Sci* 1988; 75(2):203-207.
22. Mune T, Yasuda K, Ishii M, Matsunaga T, Miura K. Tetany due to hypomagnesemia induced by cisplatin and doxorubicin treatment for synovial sarcoma. *Intern Med* 1993; 32(5):434-437.

23. el Weshi A, Thieblemont C, Cottin V, Barbet N, Catimel G. Cisplatin-induced hyponatremia and renal sodium wasting. *Acta Oncol* 1995; 34(2):264-265.
24. Hutchison FN, Perez EA, Gandara DR, Lawrence HJ, Kaysen GA. Renal salt wasting in patients treated with cisplatin. *Ann Intern Med* 1988; 108(1):21-25.
25. Lee YK, Shin DM. Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer. *Korean J Intern Med* 1992; 7(2):118-121.
26. Pezonaga I, Taylor A, Dobrota M. The effects of platinum chemotherapy on essential trace elements. *Eur J Cancer Care (Engl)* 1996; 5(2):122-126.
27. Rodriguez M, Solanki DL, Whang R. Refractory potassium repletion due to cisplatin-induced magnesium depletion. *Arch Intern Med* 1989; 149(11):2592-2594.
28. Tanaka H, Ishikawa E, Teshima S, Shimizu E. Histopathological study of human cisplatin nephropathy. *Toxicol Pathol* 1986; 14(2):247-257.
29. Safirstein R, Winston J, Goldstein M, Moel D, Dikman S, Guttenplan J. Cisplatin nephrotoxicity. *Am J Kidney Dis* 1986; 8(5):356-367.

30. Bompart G. Cisplatin-induced changes in cytochrome P-450, lipid peroxidation and drug-metabolizing enzyme activities in rat kidney cortex. *Toxicol Lett* 1989; 48(2):193-199.
31. Lam M, Adelstein DJ. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. *Am J Kidney Dis* 1986; 8(3):164-169.
32. Daugaard G, Rossing N, Rorth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. *Cancer Chemother Pharmacol* 1988; 21(2):163-167.
33. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP. Renal tubular function in patients treated with high-dose cisplatin. *Clin Pharmacol Ther* 1988; 44(2):164-172.
34. Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, et al. Comparison of methods of evaluating nephrotoxicity of cis-platinum. *Clin Pharmacol Ther* 1980; 27(4):557-562.
35. Verplanke AJ, Herber RF, de Wit R, Veenhof CH. Comparison of renal function parameters in the assessment of cis-platin induced nephrotoxicity. *Nephron* 1994; 66(3):267-272.
36. Kubota A, Yoshida T, Tsukuda M, Furukawa S, Miyata K, Mochimatsu I, et al. Measurement of creatinine clearance and urinary NAG for the evaluation of cis-platinum induced

- nephrotoxicity. *Gan To Kagaku Ryoho* 1989; 16(8 Pt 1):2599-2605.
37. Reed E, Jacob J, Brawley O. Measures of renal function in patients with cisplatin-related chronic renal disease. *J Natl Med Assoc* 1991; 83(6):522-526.
 38. Ikeda H, Nagashima K, Okumura H, Takahashi A, Matsuyama S, Nagamachi Y. Urinary excretion of beta 2-microglobulin and N-acetyl- β -D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II). *Eur J Surg Oncol* 1988; 14(1):17-20.
 39. Price RG. The role of NAG (N-acetyl- β -D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. *Clin Nephrol* 1992; 38 Suppl 1:S14-S19.
 40. Lorini R, Scaramuzza A, Cortona L, Valenti G, d'Annunzio G, Melzi d'Eril GV. Increased urinary N-acetyl- β -glucosaminidase (NAG) excretion in young insulin-dependent diabetic patients. *Diabetes Res Clin Pract* 1995; 29(2):99-105.
 41. Wiland P, Szechinski J. N-acetyl- β -D-glucosaminidase enzymuria as an indicator in monitoring the therapy of some rheumatic diseases with potentially nephrotoxic drugs. *Arch Immunol Ther Exp (Warsz)* 1994; 42(4):331-336.
 42. Wiland P, Swierkot J, Szechinski J. N-acetyl- β -D-glucosaminidase urinary excretion as an early indicator of kidney dysfunction in rheumatoid arthritis patients on low-

- dose methotrexate treatment. *Br J Rheumatol* 1997; 36(1):59-63.
43. Nekulova M, Mechl Z, Kerpel-Fronius S, Skalkova D, Sopkova B. The excretion of urinary enzymes, proteins and creatinine in patients receiving cisplatinum. *Neoplasma* 1987; 34(2):183-188.
44. Hayashi M, Numaguchi M, Watabe H, Enomoto H, Yaoi Y. Cisplatin-induced nephrotoxicity and the protective effect of fosfomycin on it as demonstrated by using a crossover study of urinary metabolite levels. *Acta Obstet Gynecol Scand* 1997; 76(6):590-595.
45. De Broe ME, Wedeen RP. Prevention of cisplatin nephrotoxicity. *Eur J Cancer Clin Oncol* 1986; 22(9):1029-1031.
46. Pinzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP, Balmes P. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. *Cancer Chemother Pharmacol* 1994; 35(1):1-9.
47. Yogi S, Ikeuchi T, Kai Y. Prophylactic effect of fosfomycin on CDDP nephrotoxicity. *Hinyokika Kyo* 1989; 35(4):615-621.
48. Yoshida K, Takahashi T, Nakame Y, Saitoh H, Horiuchi S, Kaneoya F, et al. Urinary NAG and gamma-GTP activities as indicators of CDDP renal toxicity: effect of fosfomycin on CDDP renal toxicity. *Hinyokika Kyo* 1986; 32(9):1237-1245.

49. Kumano N, Koinumaru S, Oizumi K, Konno K. cis-Diamminedichloroplatinum (CDDP)-fosfomycin (FOM) combination in lung cancer patients with respect to the peripheral T lymphocyte subsets. *Tohoku J Exp Med* 1986; 148(3):333-334.
50. Olson JJ, Truelson JM, Street N. *In vitro* interaction of cisplatin and fosfomycin on squamous cell carcinoma cultures. *Arch Otolaryngol Head Neck Surg* 1994; 120(11):1253-1257.
51. Inouye S, Niizato T, Komiya I, Yuda Y, Yamada Y. Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats. *J Pharmacobiodyn* 1982; 5(12):941-950.
52. Inouye S, Niizato T, Takeda U, Koeda T. Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin. *J Pharmacobiodyn* 1982; 5(9):659-669.
53. Package inserts. Japan Pharmaceutical Reference. 5th ed. Fujitsu Learning Media Limited, 1999; 524-527.
54. Kirby WM. Pharmacokinetics of fosfomycin. *Chemotherapy* 1977; 23 Suppl 1:141-151.
55. Monographs on drugs and ancillary substances. Antibacterial Agents. In: Reynolds FEF, editor. *Martindale The Extra Pharmacopoeia*, 31st ed. London: Royal Pharmaceutical Society of Great Britain, 1996; 232-233.

56. Nakachi K, Limtrakul P, Sonklin P, Sonklin O, Jareern CT, Lipigorngoson S, et al. Risk factors for lung cancer among Northern Thai women: epidemiological, nutritional, serological, and bacteriological surveys of residents in. *Jpn J Cancer Res* 1999; 90(11):1187-1195.
57. Haskell CM, Holmes EC. Non-small cell lung cancer. *Curr Probl Cancer* 1987; 11(1):1-53.
58. Ihde DC, Minna JD. Non-small cell lung cancer. Part I: Biology, diagnosis, and staging. *Curr Probl Cancer* 1991; 15(2):61-104.
59. Lee CT. Non-surgical therapy for the patients with advanced non-small cell lung cancer. *Respirology* 1998; 3(3):159-166.
60. Ochmanski W. Current capabilities and procedures for diagnosing lung neoplasms. *Przegl Lek* 1997; 54(2):126-134.
61. Clarke SJ, Boyer MJ. Non-surgical therapy for patients with advanced non-small cell lung cancer. *Respirology* 1998; 3(3):175-182.
62. Liao M. Non-surgical therapy for patients with advanced non-small cell lung cancer. *Respirology* 1998; 3(3):151-157.
63. Thongprasert S. Analysis of the four combination chemotherapies in non-small cell lung cancer treated at Maharaj Nakorn Chiang Mai Hospital. *Gan To Kagaku Ryoho* 1992; 19(8 Suppl):1197-1201.

64. Pascoe JM, Roberts JJ. Interactions between mammalian cell DNA and inorganic platinum compounds. I. DNA interstrand cross-linking and cytotoxic properties of platinum(II) compounds. *Biochem Pharmacol* 1974; 23(9):1359-1365.
65. Pinto AL, Lippard SJ. Binding of the antitumor drug cis-diamminedichloroplatinum(II) to DNA. *Biochim Biophys Acta* 1985; 780(3):167-180.
66. Jeha S, Jaffe N, Robertson R. Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminedichloroplatinum-II-based regimen for osteosarcoma. *Med Pediatr Oncol* 1992; 20(1):71-74.
67. Blommaert FA, Dijk-Knijnenburg HC, Dijt FJ, den Engelse L, Baan RA, Berends F, et al. Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences *in vitro* and in cells. *Biochemistry* 1995; 34(26):8474-8480.
68. Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA. Clinical kinetics on intact cisplatin and some related species. *Clin Pharmacol Ther* 1981; 29(5):658-664.
69. Bajorin DF, Bosl GJ, Alcock NW, Niedzwiecki D, Gallina E, Shurgot B. Pharmacokinetics of cis-diamminedichloroplatinum (II) after administration in hypertonic saline. *Cancer Res* 1986; 46(11):5969-5972.
70. Vermorken JB, van der Vijgh WJ, Klein I, Hart AA, Gall HE, Pinedo HM. Pharmacokinetics of free and total platinum

species after short-term infusion of cisplatin. *Cancer Treat Rep* 1984; 68(3):505-513.

71. Chabner BA, Allegra CJ, Calabresi P. Antineoplastic agents. In: Gilman AG, editor. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 9th ed. New York: McGraw-Hill, Inc., 1996; 1233-1287.
72. Pearson BS, Raghavan D. First-line intravenous cisplatin for deeply invasive bladder cancer: update on 70 cases. *Br J Urol* 1985; 57(6):690-693.
73. Ozols RF, Corden BJ, Jacob J, Wesley MN, Ostchega Y, Young RC. High-dose cisplatin in hypertonic saline. *Ann Intern Med* 1984; 100(1):19-24.
74. Colvin OM. Alkylating agents and platinum antitumor compounds. In: Pine JW Jr, editor. *Cancer Medicine*, 4th ed. Maryland: William & Wilkins, 1997; 949-975.
75. Mavichak V, Wong NL, Quamme GA, Magil AB, Sutton RA, Dirks JH. Studies on the pathogenesis of cisplatin-induced hypomagnesemia in rats. *Kidney Int* 1985; 28(6):914-921.
76. De Witt LM, Jones TW, Moore L. Stimulation of the renal endoplasmic reticulum calcium pump: a possible biomarker for platinate toxicity. *Toxicol Appl Pharmacol* 1988; 92(2):157-169.
77. Hrushesky WJ, Shimp W, Kennedy BJ. Lack of age-dependent cisplatin nephrotoxicity. *Am J Med* 1984; 76(4):579-584.

78. Judge TG. The milieu interieur and aging. In: Brocklehurst JC, editor. Textbook of geriatric medicine and gerontology. 2nd ed. New York: Churchill Livingstone, 1978; 117-124.
79. Al Sarraf M, Fletcher W, Oishi N, Pugh R, Hewlett JS, Balducci L, et al. Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a southwest oncology group study. *Cancer Treat Rep* 1982; 66(1):31-35.
80. Behling H, Spieske C, Krafft W. Ototoxic side effects in patients with ovarian cancer treated with cisplatin. *Zentralbl Gynakol* 1988; 110(5):277-282.
81. Kopelman J, Budnick AS, Sessions RB, Kramer MB, Wong GY. Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing. *Laryngoscope* 1988; 98(8 Pt 1):858-864.
82. Hawthorn J, Ostler KJ, Andrews PL. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. *Q J Exp Physiol* 1988; 73(1):7-21.
83. Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB. 5-HT₃ receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. *Br J Pharmacol* 1989; 97(1):247-255.
84. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozenzweig M, Young RC, et al. Toxic effects of cis-

- dichlorodiammineplatinum(II) in man. *Cancer Treat Rep* 1979; 63(9-10):1527-1531.
85. Dance N, Price RG, Robinson D, Stirling JL. Beta-galactosidase, beta-glucosidase and N-acetyl- β -glucosaminidase in human kidney. *Clin Chim Acta* 1969; 24(2):189-197.
86. Perdichizzi G, Cucinotta D, Fera R, Di Cesare E, Campo S, Squadrito G. Correlation between urinary activity of N-acetyl- β -D-glucosaminidase (NAG) and albumin excretion rate in type II (non-insulin-dependent) diabetic subjects. *Acta Diabetol Lat* 1987; 24(2):149-155.
87. Pugh D, Walker PG. The localization of N-acetyl-D-glucosaminidase in tissues. *J Histochem Cytochem* 1961; (9):242-250.
88. Systemic Anti-Infectives. In: Kastrup EK, Hebel SK, Rivard R, editors. *Facts and Comparisons*. 1999 ed. Missouri: A Wolters Kluwer Company, 1999; 2670-2672.
89. Fujii R. Fosfomycin in the treatment of bacterial infections: summary of clinical trials in Japan. *Chemotherapy* 1977; 23 Suppl 1:234-246.
90. Barry AL, Brown SD. Antibacterial spectrum of fosfomycin trometamol [letter]. *J Antimicrob Chemother* 1995; 35(1):228-230.

91. Kawabata N, Shiraha Y, Doi S, Umemura K, Yaginuma K. A study on serum level and urinary excretion of fosfomycin-Na in man with special reference to pharmacokinetic analysis (author's transl). *Jpn J Antibiot* 1978; 31(9):549-560.
92. Shimizu K. Fosfomycin: Absorption and excretion. *Chemotherapy* 1977; 23 Suppl 1:153-158.
93. Umeki S, Watanabe M, Yagi S, Soejima R. Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity. *Am J Med Sci* 1988; 295(1):6-10.
94. Hrushesky WJ, Borch R, Levi F. Circadian time dependence of cisplatin urinary kinetics. *Clin Pharmacol Ther* 1982; 32(3):330-339.